ADCT
Income statement / Annual
Last year (2023), ADC Therapeutics SA's total revenue was $69.56 M,
a decrease of 66.86% from the previous year.
In 2023, ADC Therapeutics SA's net income was -$240.05 M.
See ADC Therapeutics SA’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$69.56 M
|
$209.91 M
|
$33.92 M
|
$0.00
|
$2.34 M
|
$1.14 M
|
$1.80 M
|
| Cost of Revenue |
$2.53 M |
$4.58 M |
$1.39 M |
$1.97 M |
$107.54 M |
$118.09 M |
$85.53 M |
| Gross Profit |
$67.03 M |
$205.33 M |
$32.52 M |
-$1.97 M |
-$105.20 M |
-$116.95 M |
-$83.73 M |
| Gross Profit Ratio |
0.96 |
0.98 |
0.96 |
0 |
-44.96 |
-102.58 |
-46.44 |
| Research and Development
Expenses |
$127.13 M
|
$187.90 M
|
$158.00 M
|
$142.03 M
|
$107.54 M
|
$118.31 M
|
$85.53 M
|
| General & Administrative
Expenses |
$48.42 M
|
$141.06 M
|
$71.46 M
|
$77.23 M
|
$13.81 M
|
$8.60 M
|
$7.81 M
|
| Selling & Marketing
Expenses |
$57.46 M
|
$69.05 M
|
$64.78 M
|
$22.10 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$105.89 M
|
$141.06 M
|
$136.24 M
|
$77.23 M
|
$13.81 M
|
$8.60 M
|
$7.81 M
|
| Other Expenses |
$0.00 |
$14.58 M |
$28.49 M |
-$46.40 M |
$388,000.00 |
$166,000.00 |
$137,000.00 |
| Operating Expenses |
$233.02 M |
$328.96 M |
$294.24 M |
$219.26 M |
$121.74 M |
$127.08 M |
$93.47 M |
| Cost And Expenses |
$235.54 M |
$333.54 M |
$295.64 M |
$219.26 M |
$121.74 M |
$127.08 M |
$93.47 M |
| Interest Income |
$10.54 M |
$17.97 M |
$66,000.00 |
$832,000.00 |
$2.25 M |
$2.86 M |
$1.03 M |
| Interest Expense |
$46.33 M |
$36.92 M |
$18.34 M |
$4.93 M |
$156,000.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$3.27 M
|
$2.39 M
|
$2.63 M
|
$1.97 M
|
$1.65 M
|
$513,000.00
|
$341,000.00
|
| EBITDA |
-$146.76 M
|
-$108.06 M
|
-$223.72 M
|
-$219.26 M
|
-$114.10 M
|
-$122.36 M
|
-$91.33 M
|
| EBITDA Ratio |
-2.11 |
-0.47 |
-6.87 |
0 |
-48.65 |
-110.01 |
-51.11 |
| Operating Income Ratio
|
-2.39
|
-0.59
|
-7.72
|
0
|
-51.03
|
-110.47
|
-50.84
|
| Total Other
Income/Expenses Net |
-$29.43 M
|
-$33.56 M
|
$10.22 M
|
-$26.70 M
|
$3.50 M
|
$3.07 M
|
$1.86 M
|
| Income Before Tax |
-$195.42 M |
-$154.66 M |
-$251.51 M |
-$245.96 M |
-$115.90 M |
-$122.87 M |
-$89.81 M |
| Income Before Tax Ratio
|
-2.81
|
-0.74
|
-7.42
|
0
|
-49.53
|
-107.78
|
-49.81
|
| Income Tax Expense |
$39.11 M |
$1.14 M |
-$21.48 M |
$327,000.00 |
$582,000.00 |
$224,000.00 |
$48,000.00 |
| Net Income |
-$240.05 M |
-$155.80 M |
-$230.03 M |
-$246.29 M |
-$116.48 M |
-$123.10 M |
-$89.86 M |
| Net Income Ratio |
-3.45 |
-0.74 |
-6.78 |
0 |
-49.78 |
-107.98 |
-49.84 |
| EPS |
-2.94 |
-1.99 |
-3 |
-3.77 |
-1.74 |
-2.29 |
-1.53 |
| EPS Diluted |
-2.94 |
-1.99 |
-3 |
-3.77 |
-1.74 |
-2.29 |
-1.53 |
| Weighted Average Shares
Out |
$81.71 M
|
$78.15 M
|
$76.75 M
|
$65.41 M
|
$66.87 M
|
$53.83 M
|
$58.85 M
|
| Weighted Average Shares
Out Diluted |
$81.71 M
|
$78.15 M
|
$76.75 M
|
$65.41 M
|
$66.87 M
|
$53.83 M
|
$58.85 M
|
| Link |
|
|
|
|
|
|
|
